Can MRI T₁ be used to detect early changes in 5xFAD Alzheimer’s mouse brain?

Nicholas G. Spencer¹ · David P. Lovell² · Kay Elderfield³ · Brian Austen⁴ · Franklyn A. Howe⁴

Abstract

Objectives In the present study, we have tested whether MRI T₁ relaxation time is a sensitive marker to detect early stages of amyloidosis and gliosis in the young 5xFAD transgenic mouse, a well-established animal model for Alzheimer’s disease.

Materials and methods 5xFAD and wild-type mice were imaged in a 4.7 T Varian horizontal bore MRI system to generate T₁ quantitative maps using the spin-echo multislice sequence. Following immunostaining for glial fibrillary acidic protein, Iba-1, and amyloid-β, T₁ and area fraction of staining were quantified in the posterior parietal and primary somatosensory cortex and corpus callosum.

Results In comparison with age-matched wild-type mice, we observed first signs of amyloidosis in 2.5-month-old 5xFAD mice, and development of gliosis in 5-month-old 5xFAD mice. In contrast, MRI T₁ relaxation times of young, i.e., 2.5- and 5-month-old, 5xFAD mice were not significantly different to those of age-matched wild-type controls. Furthermore, although disease progression was detectable by increased amyloid-β load in the brain of 5-month-old 5xFAD mice compared with 2.5-month-old 5xFAD mice, MRI T₁ relaxation time did not change.

Conclusions In summary, our data suggest that MRI T₁ relaxation time is neither a sensitive measure of disease onset nor progression at early stages in the 5xFAD mouse transgenic mouse model.

Keywords Alzheimer’s disease · Transgenic mice · Magnetic resonance imaging · Alzheimer beta-protein · Inflammation

Abbreviations

5xFAD Five familial Alzheimer’s disease mutations
Aβ Amyloid-β
AD Alzheimer’s disease
FOV Field of view
GFAP Glial fibrillary acidic protein
Iba-1 Ionized calcium binding adaptor molecule 1
PET Positron emission tomography
Mo Month
MRI Magnetic resonance imaging
ROI Region of interest
TE Echo time
TR Repetition time
WT Wild-type

Introduction

Alzheimer’s disease (AD) is clinically characterised by the increasing decline of cognitive functions that eventually leaves the patient dependent on custodial care. Studies in sporadic and autosomal dominant AD support a sequence of pathological changes, namely increased brain amyloidosis, tau pathology, decreased glucose metabolism,
neurodegeneration, and brain atrophy—with amyloidosis being the earliest component, starting years or even decades before clinical symptoms, i.e., cognitive decline, begin to show [1–3]. In addition, there is now good evidence for neuroinflammation in the brain of AD patients [4, 5]. Activated microglia and astrocytes appear to play key roles in regulating AD pathogenesis, while they can have both protective and detrimental effects [6–15].

Current diagnostic criteria used to identify AD in people with dementia rely on advanced neurological impairment—which is irreversible with current treatment options. To date, diagnostic markers that are sensitive to early disease stages are not available. Early biomarkers of AD can aid presymptomatic diagnosis, drug development by providing surrogate endpoints, treatment decisions, and disease monitoring [16]. Neuroimaging techniques using positron emission tomography (PET) exist to measure changes in glucose metabolism, currently the most common diagnostic criterion for AD [17], and also amyloid-β (Aβ) deposition, tau aggregation, and neuroinflammation. Magnetic resonance imaging (MRI) is also recognised as an important tool in AD diagnosis and has some advantages over PET in that it is cheaper and currently more widely available. MRI enables visualisation of the medial temporal lobe, in which atrophy is related to AD and its severity [18, 19]. Although MRI is already routinely used to monitor disease progression at late stages of AD, i.e., after the onset of cognitive decline, it remains unclear whether this technique can also be applied to identify early changes in the brain of AD patients before clinical symptoms become apparent.

In a cross-sectional analysis of 21 subjects with AD and 32 similarly aged healthy controls, AD was characterised by reduced quantitative $T_1$ and $T_2$ values [20]. In previous work by the same authors, decreased $T_1$ values were found in patients with dementia with Lewy bodies compared with control subjects, highlighting the potential of $T_1$ measures in general to detect changes caused by neurodegeneration [21]. Using 5xFAD transgenic mice, a well-recognised AD mouse model [22–24], we have previously shown that at the age of 11 months, 5xFAD mice have reduced MRI $T_1$ relaxation times in the lower layers of the posterior parietal and primary somatosensory areas of the cortex and the corpus callosum compared with age-matched wild-type controls [25]. The cortex has a complex architecture that is made up of several layers, each defined by varying densities of myelin, neuronal cells, and receptors [26]. Aβ deposition also follows a layered pattern in the cortex [25, 27]; regional variations of tissue changes related to Aβ deposition, gliosis, and/or neuronal loss may not be captured in large regions of interest that include less affected areas of tissue. We previously found in the cortex of 11-month-old 5xFAD mice a pattern of $T_1$ reductions that broadly correspond to the pattern of Aβ reduction [25]. This indicates that quantitative MRI can provide information about tissue changes in specific regions of the mouse brain provided regions of interest (ROI) are placed appropriately. Due to the higher spatial resolution allowed by quantitative $T_1$ MRI than diffusion tensor imaging and magnetisation transfer ratio MRI, quantitative $T_1$ measurements have better chance of detecting changes in small regions of the brain. Here, we have extended these studies on young 5xFAD mice to test whether the determination of MRI $T_1$ relaxation times is a sensitive method capable of identifying early changes in the AD mouse brain, such as the beginning of amyloidosis and gliosis.

**Materials and methods**

**Transgenic mice**

This study was carried out in strict accordance with the UK Home Office Animals Scientific Procedures Act 1986. The protocol was approved by the committee of the UK Home Office (PPL number: 70/7075). All efforts were made to minimise suffering. Mice were purchased from Jackson Laboratory (5xFAD strain name: B6SJL-Tg[APPSwF1Lon, PSEN1* M146L*L286 V] J6799Vas/Mmjax]; stock number: 006554; and non-carrying [wild-type] mice strain name: B6SJF1/J; stock number: 100012). A colony of transgenic and wild-type controls was produced by crossing hemizygous 5xFAD mice with wild-type mice. Mice were genotyped using polymerase chain reaction and gel electrophoresis. Eleven young mice [five wild-type and six 5xFAD (mean age = 2.6 months, SD = 0.16)] and ten older mice [five wild-type and five 5xFAD (mean age = 5.2 months, SD = 0.21)] were imaged. For simplicity, we describe these ages as 2.5 and 5 months throughout this report. A mixture of males and females were used in all groups. To compare Aβ load in young 5xFAD mice with that of old mice, we additionally quantified Aβ load in stained sections from 11-month-old mice that were previously obtained using the same methods of animal breeding and immunohistochemistry.

**In vivo MRI**

In vivo MR images were acquired on a 4.7 T Varian horizontal bore MRI system with a mouse brain coil setup comprising a volume transmit coil and surface coil receiver (RAPID Biomedical GmBH, Würzburg-Rimpur, Germany). Mice were initially anaesthetised with isoflurane, consisting of an O$_2$ mixture (2 L/min), administered in a sealed tank fitted to an isoflurane scavenger system. Subsequently, a 1:2:1 mixture of Hypnorm (0.315 μg/mL fentanyl citrate and 10 mg/mL fluanisone), sterile water, and
Hypnovel (5 mg/mL midazolam) was administered intraperitoneally at 10 mg/kg bodyweight. Body temperature was maintained by a warming bed integrated into the imaging coil apparatus.

For each mouse, five images were acquired using the spin echo multi-slice sequence with repetition times (TR) of 250, 500, 1000, 2000, 4000 ms and 16, 8, 4, 2, 2 averages, respectively, to maintain a similar signal-to-noise ratio for each TR. Other imaging parameters remained constant for all images: echo time (TE) = 14 ms; field of view = 30 × 30 mm; matrix = 128 × 128; nine contiguous slices of 1 mm thickness with the most anterior of the nine slices positioned just behind the olfactory bulb; total acquisition time = 51.2 min. The range of TRs used was chosen so to adequately quantify the range of T1 relaxation times in the mouse brain. Immediately after imaging, the mouse was culled using the Schedule 1 method (dislocation of the neck) and the brain was placed in formalin with the skull left intact to retain the shape of the brain. All brain samples were soaked in formalin for 5 days before being processed for immunohistochemistry.

**Immunohistochemistry**

Fixed brains were removed from the skull and sliced into 1 mm thick coronal sections using a matrix to match the imaging slices taken during MRI. Serial sections taken from the 1 mm mouse brain slices were stained for glial fibrillary acidic protein (GFAP) [Novocastra mouse monoclonal clone GA5 supplied by Leica Microsystems, Newcastle-upon-Tyne, UK (product code: NCL-GFAP-GA5)], ionized calcium binding adaptor molecule 1 (Iba-1) [MenaPath rabbit Polyclonal antibody supplied by A. Menarini Diagnostics, Wokingham, UK (product code: MP-290-CR05)], and Aβ [Novocastra mouse monoclonal Aβ clone 6F/3D supplied by Leica Microsystems, Newcastle-upon-Tyne, UK (product code: NCL-B-Amyloid)]. For GFAP and Iba-1 staining, antigen retrieval was carried out using Epitope Retrieval Solution, pH 6 at 100 °C for 30 min; GFAP antibody was applied for 15 min at a dilution of 1:200 and Iba-1 antibody was applied for 15 min at a dilution of 1:800. For Aβ staining, sections were treated with Epitope Retrieval Solution, pH 9 at 100 °C for 30 min and 90% (v/v) formic acid for 5 min; Aβ antibody was applied for 15 min at a dilution of 1:50. Immunohistochemical staining was carried out using Bond III fully automated staining system with their Bond Polymer Refine detection system and associated reagents, supplied by Leica Microsystems, Newcastle-upon-Tyne, UK. This automated system provides high sensitivity and reproducibility in immunohistochemical staining. Digital images of the histological slides were captured using a Nikon Super Coolscan 8000 ED camera, at 100% scale and 4000 pixels/in, and using the same settings for all images.

**Quantification of T1 relaxation times and immunohistochemical marker area fraction**

ImageJ software (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997–2012) [28] was used to generate T1 quantitative maps. For each dataset, MR images at each TR were normalised by dividing the number of averages in its acquisition using the ImageJ maths function, and images were stacked and co-registered using the plugin, Stackreg (Theseven et al., Lausanne, Switzerland, 1998) [29]. T1 quantitative maps were generated from the stacked images using the MRI Analysis Calculator ImageJ plugin (https://imagej.nih.gov/ij/plugins/mri-analysis.html) by Karl Schmidt. Mean T1 relaxation times were recorded for areas that covered the lower cortex and corpus callosum. This was done for the lower cortex by placing three small ROIs (4 pixels × 4 pixels) each in the left and right hemispheres that covered the lower layers of the posterior parietal and primary somatosensory areas of the cortex (a region we call lower cortex). For the corpus callosum, two ROIs (5 pixels × 2 pixels) were placed directly below the ROIs placed in the lower cortex and over the dark area corresponding to dense myelin areas of the corpus callosum. The use of multiple ROIs, as opposed to one hand drawn selection, was chosen so to cover a large enough area whilst keeping the area and placement of ROIs consistent between all mice.

ImageJ was used to calculate the area fraction of positive staining (percentage pixels in the ROI that have been highlighted using the threshold function). The method for calculating area fraction was followed as described in the online ImageJ documentation, http://rsbweb.nih.gov/ij/docs/examples/stained-sections/index.html. Red–green–blue images were converted to 8-bit, grey scale images; a set threshold level was chosen for each of the three immunological stains that selected the areas of positive staining but did not include other areas (upper and lower threshold values: Aβ = 0–180; GFAP = 0–210; Iba-1 = 0–220). ROIs in the MR images were transferred to approximately the same anatomical regions in the histological images and increased in size by a factor of 12, equal to the difference in scale factor of the MR and histological images, and area fraction was calculated automatically.

**Statistics**

All data are presented as mean ± SEM. Statistical significance of differences between experimental groups was evaluated using the SPSS software [IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0.  Springer]
Armonk, NY, USA: IBM Corp (http://www.IBM.com)].

Following a one-way analysis of variance (ANOVA) in a $2 \times 2$ factorial design, means were compared using Fisher’s unprotected least significant difference test. An additional analysis was made on the 5xFAD mice to compare the lower cortex with corpus callosum for each of the histological markers Aβ, GFAP, and Iba-1 using a paired $t$ test. Data were considered to be statistically significant with $p < 0.05$. To compare Aβ load in young 5xFAD mice with that of old mice, one-way ANOVA was used to determine whether any differences between group means, i.e., Aβ load in the lower cortex and corpus callosum of 2.5-, 5-, and 11-month-old mice, were statistically significant.

Results

Quantification of Aβ load and gliosis in young 5xFAD mice

To understand whether the quantified $T_1$ relaxation time can be used to detect early changes in the brain of young 5xFAD mice, immunohistochemistry was first applied in order to determine time points of Aβ plaque development and accompanied neuroinflammation. Although it has been reported previously that Aβ deposition and gliosis begin in some brain regions of 5xFAD mice at the age of 2 months and increase steadily afterwards [22], to date no quantitative data are available characterising Aβ load and neuroinflammation (1) in different brain regions and (2) at different ages of 5xFAD mice. To determine early changes in the brain of 5xFAD mice, we quantified Aβ deposition, astrocytosis and microgliosis in brains of 2.5- and 5-month-old 5xFAD mice and age-matched wild-type mice. Aβ staining (to determine Aβ plaque development), GFAP staining (to quantify activated astrocytes) and Iba-1 staining (to quantify activated microglial cells) were analysed in two brain regions, namely the lower cortex and the corpus callosum. We focussed specifically on these two brain regions, as they have been identified as areas with the largest differences in MRI $T_1$ relaxation time upon comparison of 11-month-old wild-type and 5xFAD mice [23].

Quantification of astrocytosis and microgliosis in young 5xFAD mice

First, we quantified area fraction of GFAP staining in lower cortex and corpus callosum of 2.5- and 5-month-old wild-type and 5xFAD mice. There was a statistically significant difference between groups in the lower cortex ($p < 0.05$) and the corpus callosum ($p < 0.05$) as determined by one-way ANOVA. The Fisher’s unprotected least significant difference test was used to show which groups differed from each other. As demonstrated in Fig. 1, in both brain regions, GFAP staining was not significantly different between wild-type and 5xFAD mice at the age of 2.5 months ($p = 0.324$ for lower cortex; $p = 0.343$ for corpus callosum; WT $n = 5$, 5xFAD $n = 6$). However, at the age of 5 months, significant differences were found in the area fraction of GFAP staining between wild-type and 5xFAD mice for both regions. In comparison with wild-type mice, in 5xFAD mice, GFAP area fraction was 16-fold larger.
(p < 0.01; WT n = 5, 5xFAD n = 5) in the lower cortex, and fourfold larger (p < 0.01; WT n = 5, 5xFAD n = 5) in the corpus callosum. Furthermore, GFAP area fraction was significantly larger in corpus callosum than in the lower cortex of both 2.5- and 5-month-old mice (p < 0.05 in both cases). In comparison with 2.5-month-old 5xFAD mice, GFAP area fraction of 5-month-old 5xFAD mice was threefold increased (p < 0.05) in the lower cortex, but only numerically higher in the corpus callosum [twofold increased (p = 0.083)].

Furthermore, analyses of Iba-1 staining were performed to study microgliosis in young 5xFAD mice. Figure 2 shows an example of a brain slice stained with Iba-1 and summarises results of Iba-1 staining in the lower cortex and corpus callosum in wild-type and 5xFAD mice at the age of 2.5 and 5 months. Qualitatively, Iba-1 staining was similar to that obtained for GFAP staining. There was a statistically significant difference between groups in the lower cortex (p < 0.01) and the corpus callosum (p < 0.01) as determined by one-way ANOVA. Analysis of the lower cortex and of the corpus callosum did not reveal any significant differences in area fraction of Iba-1 staining between 2.5-month-old wild-type and 5xFAD mice (p = 0.972 for lower cortex; p = 0.600 for corpus callosum; WT n = 3, 5xFAD n = 6). In contrast, Iba-1 staining was much more pronounced in 5-month-old 5xFAD mice compared with 5-month-old wild-type mice. In 5-month-old 5xFAD mice, area fraction of Iba-1 staining was 12-fold higher in the lower cortex (p < 0.01; WT n = 5, 5xFAD n = 5) and sixfold higher in the corpus callosum (p < 0.01; WT n = 5, 5xFAD n = 5) in comparison with the corresponding brain areas of wild-type mice. No differences were found in Iba-1 area fraction between lower cortex and corpus callosum of either 2.5- or 5-month-old 5xFAD mice (p = 0.077 and p = 0.334, respectively). Iba-1 area fraction in the lower cortex (fourfold; p < 0.01) and corpus callosum (sixfold; p < 0.01) increased significantly in 5-month-old 5xFAD mice compared with 2.5-month-old 5xFAD mice.

Quantification of Aβ load in young 5xFAD mice

Analysis with one-way ANOVA found statistically significant differences between groups in the lower cortex (p < 0.001) and corpus callosum (p < 0.001). No significant Aβ staining was detectable in the brain of wild-type mice of both age groups. However, in agreement with Oakley et al. [22], Aβ staining was visible in 5xFAD mice as young as 2.5-months-old. Staining was more pronounced in the lower cortex than in the corpus callosum. In 2.5-month-old 5xFAD mice, Aβ area fraction in the lower cortex was 96-fold higher (p < 0.05) than in the corpus callosum. Similar to observations made for 2.5-month-old mouse brains, higher amounts of Aβ were detected in the lower cortex than in the corpus callosum of 5-month-old 5xFAD mice (Fig. 3). In comparison with 5-month-old WT mice, in 5-month-old 5xFAD mice, Aβ deposition was substantially enhanced in both brain regions investigated (lower cortex: p < 0.001; corpus callosum: p < 0.001; WT n = 5, 5xFAD n = 5) (Fig. 3). Furthermore, compared with 2.5-month-old 5xFAD mice, Aβ area fraction was significantly increased in the lower cortex (threefold; p < 0.001) and corpus callosum (111-fold; p < 0.001) of 5-month-old 5xFAD mice.
Quantification of Aβ load in old 5xFAD mice

Substantial Aβ plaque load has previously been reported for both brain regions, the lower cortex and corpus callosum, in old 5xFAD mice [22, 25]. To compare Aβ load in lower cortex and corpus callosum of young 5xFAD mice with that of old mice, we additionally quantified Aβ area fraction in brain slices obtained from 11-month-old mice using the method described above. Analysis with one-way ANOVA found statistically significant differences between groups in the lower cortex (p < 0.001) and corpus callosum (p < 0.001). In the lower cortex, Aβ area fraction of 11-month-old 5xFAD mice was 70-fold (p < 0.001; 2.5 mo n = 5, 11 mo n = 6) higher than that of 2.5-month-old mice and 23-fold (p < 0.001) higher than that of 5-month-old 5xFAD mice. Similarly, in the corpus callosum, a much higher Aβ load was found for 11-month-old mice compared with young mice. Aβ area fraction in the corpus callosum of 11-month-old 5xFAD mice was 4090-fold (p < 0.001; 2.5 mo n = 6, 11 mo n = 6) and 37-fold (p < 0.001; 5 mo n = 5, 11 mo n = 6) increased when compared with that of 5xFAD mice at the age of 2.5 months and 5 months, respectively.

MRI T1 signals of young 5xFAD mice

We have previously reported that 11-month-old 5xFAD mice are characterised by significantly lower MRI T1 relaxation time compared to age-matched wild-type mice, while differences were most pronounced in the lower cortex and the corpus callosum (white matter) [25]. To test whether MRI T1 can be used to detect early changes in Aβ load and neuroinflammation in AD mice, we determined MRI T1 relaxation time in young wild-type and 5xFAD mice. No statistical significant differences in T1 relaxation time were found between the groups (2.5- and 5-month-old mice) as determined by one-way ANOVA, indicating that T1 relaxation times in the lower cortex as well as in the corpus callosum differed neither between wild-type and 5xFAD mice at both age groups nor between 2.5- and 5-month-old 5xFAD mice (Fig. 4).

Discussion

Histochemistry of young 5xFAD mice

In this study, we present the first quantification of amyloidosis, astrocytosis, and microgliosis in the lower cortex and the corpus callosum of young 5xFAD mice. The 5xFAD transgenic mouse was developed by Oakley et al. [22] to co-express five familial forms of Alzheimer’s disease [APP K670 N/M671L (Swedish) + I716 V (Florida) + V717I (London) and PS1 M146L + L286 V]. 5xFAD mice are characterised by the early development of Aβ plaques, neuroinflammation, neuronal loss, and memory impairment [22–24, 30, 31], all hallmarks of human Alzheimer’s disease. Therefore, these 5xFAD transgenic mice have been acknowledged as a useful model for better understanding the pathogenesis of human Alzheimer’s disease. In agreement with previous reports [22, 24], we found that first signs of amyloidosis and gliosis were detectable in the lower cortex and the corpus callosum of 2.5-month-old mice.
5xFAD mice, although area fractions of GFAP staining and Iba-1 staining did not differ significantly from those of age-matched controls. However, significant increases in both astrocytosis and microgliosis, which occurred in parallel to significant increases in the Aβ area fraction, were found in the lower cortex, as well as in the corpus callosum of 5xFAD mice at the age of 5 months. This is the same age at which first behavioural changes, namely hippocampus-dependent memory impairments, have been observed in 5xFAD mice [22, 31]. Intriguingly, quantification of Aβ plaque load in 5-month-old 5xFAD mice compared with levels in 2.5-month-old 5xFAD mice revealed only minor increases when compared with the changes between 11- and 5-month-old 5xFAD mice. Taken together, this suggests that subtle changes in brain Aβ load and/or early development of gliosis are sufficient to cause memory deficits in an Alzheimer’s disease mouse model. Our data further point to the importance of Aβ in provoking an inflammatory response, since increases in gliosis appear to follow after the deposition of Aβ.

**MRI T1 relaxation times in young 5xFAD mice**

As there is currently urgent need for diagnostic tools capable of identifying early changes in the brain of patients with Alzheimer’s disease, we asked whether MRI T1 relaxation time can be used (1) to distinguish wild-type and 5xFAD mice at an age characterised by early stages of Aβ plaque deposition and neuroinflammation and (2) to monitor disease progression in young 5xFAD mice. In a previous study, we have found that MRI T1 of the lower cortex and the corpus callosum were significantly different between 11-month-old 5xFAD mice and age-matched wild-type controls [25]. Brain tissue T1 is dependent on tissue water content [32] and is influenced by a variety of factors, which can include myelin density, axonal damage, oedema, or widening of extracellular space [33]. However, the observed early development of amyloidosis and gliosis in young 5xFAD mice was not accompanied by significant changes in MRI T1 relaxation time. The T1 differences are small between 5-month-old WT and 5xFAD mice, representing a 6–7% change in the lower cortex and corpus callosum; and there was not a significant difference between T1 relaxation times of 2.5- and 5-month-old 5xFAD. In a previous study [25] we found T1 reductions confined to specific brain regions, for example, the deep layers of the cortex; therefore, ROIs must be sized and placed appropriately to be able to capture these changes. Despite focusing our attention on the lower cortex and corpus callosum, T1 values were not significantly different between 5-month-old 5xFAD and WT mice. Other studies have found no T1 differences between AD and WT mice, for example, in PS/APP mice 16–23 months old [34], and in ArcAβ mice, which have similar T1 values to WT mice irrespective of age [35]. It is not known, however, if the lack of T1 change in those studies is due to the size and placement of ROIs or the use of different AD transgenic models.

We have suggested previously that the presence of Aβ plaques may explain differences in MRI T1 between 11-month-old wild-type and 5xFAD mice [25]. However, since the beginning of Aβ plaque deposition cannot
be reliably detected by MRI $T_1$, this suggests that only substantial Aβ load causes significant changes in MRI $T_1$ (e.g., in the corpus callosum of 11-month-old mice, WT $T_1 = 1.85$ s versus 5xFAD $T_1 = 1.72$ s). This hypothesis is supported by our finding that the Aβ area fractions in lower cortex and corpus callosum of 11-month-old 5xFAD mice were more than 20–30 times larger than those determined for the corresponding brain regions in 5-month-old mice. In general, reports from other research laboratories of significant $T_1$ differences between AD and wild-type mice were in old mice when Aβ deposition is fully established [36, 37]. Thus, an insufficient amount of Aβ in young 5xFAD mice could explain the lack of large differences in MRI $T_1$ relaxation times between young wild-type and 5xFAD mice. We cannot exclude that there might have been $T_1$ differences in other brain regions of the AD mouse, for example, the subiculum [36]; in this work, analysis was restricted to the lower cortex and corpus callosum, where there are easily identifiable anatomical boundaries that help to minimise the subjective nature of ROI placement, and where $T_1$ changes in old mice were previously identified [25]. Nevertheless, it should be noted that there is still the possibility that differences will be found in MRI studies at high magnetic field strengths (7.0 T and above) that provide higher signal-to-noise ratio and improved spatial resolution, with $T_2$ or $T_2^*$-weighted imaging, which enables the detection of individual Aβ plaques in the mouse [38–42], ex vivo human [43], and plaque-like pathology in vivo human brain [44], and, given the slow rate of Aβ deposition decades prior to the onset of clinical symptoms in AD [2], direct visualisation of plaques as opposed to measuring indirect effects related to Aβ deposition may provide a better early diagnostic tool. However, there are unresolved questions over the specificity of this technique, and to date, most clinical studies use the lower field strength 3 T MRI. Further work is needed to develop diagnostic tools capable of detecting early changes in the brain of AD patients. Previous investigations have found magnetisation transfer ratio measurements a useful means of assessing changes in tissue integrity that may involve gliosis [45–47] (an early event in AD); it would be of interest to assess other MRI methods such as MTR to give quantitative information on the AD mouse brain.

In providing in vivo evaluation of Aβ deposition, PET is closer to clinical application than MRI. PET tracers that allow direct, in vivo visualisation of Aβ are advancing in their development and may allow early detection and monitoring of treatment response. Increased Pittsburgh Compound B retention is found in AD patients compared with controls [48, 49], and florbetaben, the third amyloid imaging agent to be approved for clinical use (Amyvid [Florbetapir F 18] was approved by the FDA in 2012 [50], and Vizamyl [Flutemetamol F 18] was approved by the FDA in 2013 [51]), demonstrated high sensitivity and specificity for detecting Aβ deposits, and high negative predictive value [52]. That said, large-scale controlled trials are needed to assess further the usefulness of these techniques in people with early stage AD, who are more likely to benefit from treatment intervention targeting amyloid pathology. Furthermore, it is still important to assess other potential imaging modalities that may have use within the AD diagnostic framework as Aβ-targeted PET is not yet capable of diagnosing AD on its own.

The strength of this study is in the quantitative analysis of histological markers Aβ, GFAP, and Iba-1 in young 5xFAD mice, which takes into account all samples and allows a more objective analysis compared with simply describing changes seen by the eye. The limitations of this study relate to the relatively low MR imaging resolution ($0.23 \times 0.23 \times 1$ mm). Despite there being no compelling evidence to suggest the mean $T_1$ values differ between young 5xFAD and WT mice, we cannot reach a strong conclusion; repeated experiments with larger samples would be needed; however, given the very small differences in $T_1$ between 5-month-old 5xFAD and WT mice this would not be recommended based on the results of this study. The small size of the mouse brain poses challenges for high-resolution MR imaging. The use of high field MRI systems can deliver higher signal-to-noise ratio than what was achievable on the 4.7 T system used in this study; we cannot neglect the impact improved image quality and higher imaging resolution would have on improving detection. Another important limitation is the discrepancy between mouse models and AD brains, which may arise from differences in tissue composition and structure, for example, Aβ load, tissue-water content, iron accumulation, and loss of fibre tracts; therefore, the mouse model does not fully recapitulate all the features of AD. For example, important differences in the characteristics of plaques in human AD and APP/PS1 mice may provide different mechanisms of MR contrast changes: plaques in APP/PS1 mice contain less iron, but are more densely packed compared with human AD samples [53]. Using voxel-based quantification, Su et al. found that AD was characterised by reduced $T_1$ values in certain brain regions, including bilateral temporal and parietal lobes in cross-sectional comparison, and an increase in $T_1$ in the right caudate, bilateral hippocampus, parahippocampus, and thalamus in longitudinal comparison [20]. Increased $T_1$ values in white matter of AD patients has been reported [54], and taken together this demonstrates the complex nature of $T_1$ changes in the human AD brain. Caution is needed when translating results from animal to human, and it would be important for future studies to assess more than one transgenic mouse model. The difference between changes in $T_1$ values in mouse models and human AD may also arise from the relatively low
specificity of the measurement. Since brain tissue $T_1$ is dependent on a variety of factors, the effect of ongoing disease on tissue composition may confound using a simple $T_1$ relaxation time as a measure of treatment response or disease progression.

**Conclusion**

Our data do not provide sufficient evidence that the mean $T_1$ values differ between WT and 5xFAD mice at young ages (2.5 and 5 months) despite the transgenic mice having pronounced pathology by the age of 5 months compared with age-matched WT mice.

**Acknowledgements**

We would like to thank colleagues in the St. George’s Histology Department for their expertise concerning the immunohistochemical staining of tissues. This work was funded by the Alzheimer’s Association (US), Grant No. MIAD-09-130446. We would also like to thank the reviewers of this report for their thoughtful comments.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and Biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9):795–804

2. Villedime VN, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid $\beta$ deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12(4):357–367

3. Yau W-YW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE (2015) Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: a prospective cohort study. Lancet Neurol 14(8):804–813

4. Bradshaw EM, Chibnik LB, Keenan BT, Ottonelli L, Raj T, Tang A, Rosenkantz LL, Imbroya S, Lee M, Von Korff A, Initiative Alzheimer Disease Neuroimaging, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16(7):848–850

5. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 74(9):1200–1205

6. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–161

7. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD (2003) CD36 mediates the innate host response to beta-amyloid. J Exp Med 197(12):1657–1666

8. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86(19):7611–7615

9. Vom Berg J, Prokop S, Miller KR, Obst J, Kálin RE, Lapopatgi-Cabezás I, Wegner A, Mair F, Schipke CG, Peters O, Winter Y, Becher B, Heppner FL (2012) Inhibition of IL-12/IL-23 signalling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 18(12):1812–1819

10. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettemann H, Heffner PL (2013) Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 8(4):e60921

11. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 28(33):8354–8360

12. Lucin KM, O’Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, Wyss-Coray T (2013) Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron 79(5):873–886

13. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012):1774

14. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL (2004) Dystrophic microglia in the aging human brain. Glia 45(2):208–212

15. Medeiros R, LaFerla FM (2013) Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 239:133–138

16. Hapelmann H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhái WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9(7):560–574

17. Coleman RE (2005) Positron emission tomography diagnosis of Alzheimer’s disease. Neuroimaging Clin N Am 15(4):837–846

18. Jack CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O’Brien PC, Edland SD, Smith GE, Boeue BF, Tangalois EG, Koken M, Petersen RC (2002) Antemortem MRI findings correlate with...
hippocampal neuropathology in typical aging and dementia. Neurology 58(5):750–757

19. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowden DA (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58(10):1476–1482

20. Su L, Blamire AM, Watson R, He J, Aribisala B, O’Brien JT (2016) Cortical and subcortical changes in Alzheimer’s disease: a longitudinal and quantitative MRI study. Curr Alzheimer Res 13(5):534–544

21. Su L, Blamire AM, Watson R, He J, Aribisala B, O’Brien JT (2015) Tissue microstructural changes in dementia with Lewy bodies revealed by quantitative MRI. J Neuro 262(1):165–172

22. Hanson MA, Distler O, Corder EH, Tanzi RE, Renton AE, Goate AM, Donadio JD, Myers RH (2007) Intra-neuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129–10140

23. Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33(2):229–235

24. Maarouf CL, Kokjohn TA, Whiteside CM, Macias MP, Kalback WM, Sabbagh MN, Beach TG, Vassar R, Roher AE (2013) Molecular differences and similarities between Alzheimer’s disease and the 5XFAD transgenic mouse model of amyloidosis. Biochem Insights 6:1–10

25. Spencer NG, Bridges LR, Elderfield K, Amir K, Austen B, Howe FA (2013) Quantitative evaluation of MRI and histological characteristics of the 5xFAD Alzheimer mouse brain. NeuroImage 76:108–115

26. Zilles K (2004) Architecture of the human cortex—regional and laminar organization. In: Paxinos G, Mai JK (eds) The human nervous system, 2nd edn. Elsevier, Amsterdam, pp 973–1055

27. Clinton J, Roberts GW, Gentleman SM, Roysoti MC (1993) Differential pattern of beta-amyloid protein deposition within cortical sulci and gyri in Alzheimer’s disease. Neuropathol Appl Neurobiol 19(3):277–281

28. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675

29. Thévenaz P, Ruttimann UE, Unser M (1998) A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Proc 7(1):27–41

30. Landel V, Baranger K, Girard SD, Jacquet M, Baranger K, Migliorati M, Escoffier G, Thévenaz P, Ruttimann UE, Unser M (1998) A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Proc 7(1):27–41

31. Sanin J, O’Shea J, Nixon RA (2004) MRI assessment of neuropathology for in vivo measurements of water content in human nervous system, 2nd edn. Elsevier, Amsterdam, pp 973–1055

32. Bongaarts A, Ohno M, Disterhoft J, Eldik LV, Berry R, Vassar R (2006) Intra-neuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129–10140

33. Donald DJ, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barlow JR (2002) Hippocampal volume as an index of Alzheimer neuropathology in typical aging and dementia. Neurology 58(5):750–757

34. El Tannir El Tayara N, Delatour B, Le Cudennec C, Guégan M, Volk A, Dhenain M (2006) Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 22(1):199–208

35. Jack CR, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, Adriany G, Grollin OH, Grimm R, Poduslo JP (2004) In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52(6):1263–1271

36. Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33(2):229–235

37. Su L, Blamire AM, Watson R, He J, Aribisala B, O’Brien JT (2015) Tissue microstructural changes in dementia with Lewy bodies revealed by quantitative MRI. J Neuro 262(1):165–172

38. Hanson MA, Distler O, Corder EH, Tanzi RE, Renton AE, Goate AM, Donadio JD, Myers RH (2007) Intra-neuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129–10140

39. Thévenaz P, Ruttimann UE, Unser M (1998) A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Proc 7(1):27–41

40. Sanin J, O’Shea J, Nixon RA (2004) MRI assessment of neuropathology for in vivo measurements of water content in human nervous system, 2nd edn. Elsevier, Amsterdam, pp 973–1055

41. Bongaarts A, Ohno M, Disterhoft J, Eldik LV, Berry R, Vassar R (2006) Intra-neuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129–10140

42. Donald DJ, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barlow JR (2002) Hippocampal volume as an index of Alzheimer neuropathology in typical aging and dementia. Neurology 58(5):750–757

43. Diniz PRB, Velasco TR, Salmon CEG, Sakamoto AC, Leite JP, Santos AC (2011) Extratemporal damage in temporal lobe epilepsy: magnetization transfer adds information to volumetric MR imaging. Am J Neuroradiol 32(10):1857–1861

44. Bastin ME, Clayton JD, Pattie A, Gerrish IF, Wardlaw JM, Deary IJ (2009) Diffusion tensor and magnetization transfer MRI measurements of periventricular white matter hyperintensities in old age. Neurobiol Aging 30(1):125–136

45. Cercignani M, Basile B, Spanò B, Comanducci G, Fasano F, Caltagirone C, Nocentini U, Bazzali M (2009) Investigation of quantitative magnetisation transfer parameters of lesions and normal appearing white matter in multiple sclerosis. NMR Biomed 22(6):646–653

46. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savickeva I, Huang G, Estrada S, Aussen B, Deb Nath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Keivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging of individual amyloid plaques in Alzheimer’s disease patients by MR microscopy on a 7T system. J Neuroimaging 18(2):125–129

47. Diniz PRB, Velasco TR, Salmon CEG, Sakamoto AC, Leite JP, Santos AC (2011) Extratemporal damage in temporal lobe epilepsy: magnetization transfer adds information to volumetric MR imaging. Am J Neuroradiol 32(10):1857–1861

48. Bastin ME, Clayton JD, Pattie A, Gerrish IF, Wardlaw JM, Deary IJ (2009) Diffusion tensor and magnetization transfer MRI measurements of periventricular white matter hyperintensities in old age. Neurobiol Aging 30(1):125–136

49. Cercignani M, Basile B, Spanò B, Comanducci G, Fasano F, Caltagirone C, Nocentini U, Bazzali M (2009) Investigation of quantitative magnetisation transfer parameters of lesions and normal appearing white matter in multiple sclerosis. NMR Biomed 22(6):646–653

50. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savickeva I, Huang G, Estrada S, Aussen B, Deb Nath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Keivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging of individual amyloid plaques in Alzheimer’s disease patients by MR microscopy on a 7T system. J Neuroimaging 18(2):125–129

51. Donald DJ, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barlow JR (2002) Hippocampal volume as an index of Alzheimer neuropathology in typical aging and dementia. Neurology 58(5):750–757

52. Donald DJ, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barlow JR (2002) Hippocampal volume as an index of Alzheimer neuropathology in typical aging and dementia. Neurology 58(5):750–757
50. Amyvid [prescribing information]. (2012) Eli Lilly and Company. http://pi.lilly.com/us/amyvid-uspi.pdf. Accessed Oct 2016
51. Vizamyl [prescribing information]. (2013) Arlington Heights, IL: GE Healthcare. http://www3.gehealthcare.com/~/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinical%20product%20info/vizamyl/gehealthcare-vizamyl-prescribing-information.pdf. Accessed Oct 2016
52. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimer’s Dement 11(8):964–974
53. Meadowcroft MD, Connor JR, Smith MB, Yang QX (2009) Magnetic resonance imaging and histological analysis of beta-amyloid plaques in both human Alzheimer’s Disease and APP/PS1 transgenic mice. J Magn Reson Imaging JMRI 29(5):997–1007
54. Besson JA, Corrigan FM, Foreman EI, Eastwood LM, Smith FW, Ashcroft GW (1985) Nuclear magnetic resonance (NMR). II. Imaging in dementia. Br J Psychiatry 146(1):31–35